$Novo-Nordisk A/S (NVO.US)$$Eli Lilly and Co (LLY.US)$ Wall ...

Wall Street analysts continue to raise their revenue expectations for Eli Lilly's obesity treatment drug, as more companies prepare to compete for Zepbound's position.
Lilly and its competitor novo nordisk a s spons adr are dominating the field of obesity treatment drugs with high efficacy and are expected to continue to do so in the future. However, as other competing drugs begin to emerge from the lab and enter the market, there is a possibility that they may challenge Zepbound and Novo's Wegovy.

The competition has intensified in the profitable weight loss drug market.